Scarica l'app Stockscreener
0.7147
1.23%
-0.0089
Dopo l'orario di chiusura:
.64
-0.0747
-10.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.7236
Aprire:
$0.73
Volume 24 ore:
6.88M
Relative Volume:
1.70
Capitalizzazione di mercato:
$258.36M
Reddito:
$1.21M
Utile/perdita netta:
$-177.12M
Rapporto P/E:
-1.051
EPS:
-0.68
Flusso di cassa netto:
$-162.37M
1 W Prestazione:
-11.80%
1M Prestazione:
-11.48%
6M Prestazione:
-59.16%
1 anno Prestazione:
-41.42%
Intervallo 1D:
$0.7009
$0.76
Intervallo di 1 settimana:
$0.6623
$0.8462
Portata 52W:
$0.6204
$3.73
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Nome
Lexicon Pharmaceuticals Inc
Settore
Industria
Telefono
(281) 863-3000
Indirizzo
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Confronta LXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
0.7147 | 258.36M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-30 | Iniziato | Leerink Partners | Outperform |
| 2023-03-07 | Iniziato | Jefferies | Hold |
| 2022-08-12 | Iniziato | Piper Sandler | Overweight |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-18 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Downgrade | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Downgrade | Stifel | Buy → Hold |
| 2019-03-25 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Reiterato | Stifel | Buy |
| 2018-02-23 | Downgrade | Needham | Buy → Hold |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Reiterato | H.C. Wainwright | Buy |
| 2017-03-01 | Reiterato | Wedbush | Outperform |
| 2016-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-05 | Reiterato | Wedbush | Outperform |
| 2016-08-02 | Iniziato | Citigroup | Buy |
| 2016-03-02 | Reiterato | Wedbush | Outperform |
| 2015-11-09 | Reiterato | Wedbush | Outperform |
| 2015-09-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Downgrade | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista? (sotagliflozin) - Marketscreener.com
Stocks to Watch: Rumble, Lexicon Pharmaceuticals - MarketWatch
FDA rejects Lexicon's Zynquista for diabetes, kidney disease - Seeking Alpha
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - The Manila Times
Lexicon Pharma Receives FDA Rejection for Diabetes Drug Zynquista, Shifts Focus to Pain Treatment Pipeline - StockTitan
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com
Point72 Asset Management L.P. Sells 2,891,141 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Fmr LLC Has $78.29 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals (LXRX) Stock Dips Amid Market Volatility - GuruFocus.com
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 - Investing.com India
Braidwell LP Sells 7,493,366 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon completes subject enrolment for DPNP trial of LX9211 - Clinical Trials Arena
2 Generic Drug Stocks Ready to Surge in 2025 - Benzinga
The Escalator: Lexicon Pharmaceuticals, Reckitt, NIH and more - MM+M Online
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - The Manila Times
Lexicon Pharma Hits 120% Enrollment Target in Key Pain Drug Trial, Ahead of Schedule | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals to Participate in December Investor Conferences - The Manila Times
Lexicon Pharmaceuticals CEO to Present at Two Major Healthcare Conferences in December | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals shares target cut, retains buy rating on FDA letter - Investing.com UK
Lexicon pivots back to pipeline after FDA rejection - The Pharma Letter
Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Hold" Rating from Needham & Company LLC - MarketBeat
Lexicon Pharmaceuticals to cut 60% of workforce By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals to cut 60% of workforce - Investing.com India
Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown - Citeline News & Insights
Diabetes Endpoints: A1C Reduction Is ‘Still Enough,’ Just Not For Lexicon’s Sotagliflozin, US FDA Says - Citeline
Lexicon to disband sales team, lay off 60% of staff - BioPharma Dive
Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback - Reuters.com
Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization - MarketWatch
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - The Manila Times
Lexicon Pharma (LXRX) to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - StreetInsider.com
Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals appoints Ivan Cheung to board By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Lexicon Appoints Ivan H. Cheung to Board of Directors - The Manila Times
Lexicon Appoints Ivan Cheung to Board of Directors - citybiz
Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India
Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance
Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat
Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India
What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times
Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals Inc Azioni (LXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexicon Pharmaceuticals Inc Azioni (LXRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Swain Judith L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
| SOBECKI CHRISTOPHER J | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
167,055 |
| LEFKOWITZ ROBERT J MD | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
| DEBBANE RAYMOND | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
1,348,879 |
| BARKER SAM L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
87,649 |
| Amouyal Philippe | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
248,364 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):